



January 1, 2025

TERMS OF SALE

The Price List and this Terms of Sale/Return Goods Policy apply to the U.S. market only. The U.S. market includes all U.S. Territories. The Price List and Terms of Sale/Return Goods Policy are subject to change without advance notice to customers. For purposes of this Terms of Sale/Return Goods Policy, "Product" shall refer to any pharmaceutical product that is manufactured and/or marketed by Pfizer Inc. ("Pfizer")

EXCEPTION: These Terms of Sale do not apply to Pfizer designated seasonal vaccines. Please refer to Pfizer's Seasonal Vaccines Terms of Sale and Return Goods Policy.

No terms in any purchase order or any acknowledgement thereof (whether printed, stamped, typed or handwritten) issued by a customer or Pfizer distributor, except terms expressing the quantity and Product ordered, will be considered applicable to customer's purchase. No modifications of these Terms of Sale/Return Goods Policy, whether different or additional terms contained in any purchase order, acknowledgement form, or any other document will be binding on Pfizer. Unless expressly indicated to the contrary, in the event of inconsistency between the terms in any Distribution Service Agreement ("DSA") and the terms contained herein, the terms contained herein shall prevail.

All orders and any correspondence pertaining thereto should be sent to:

CUSTOMER SUPPORT CONTACT INFORMATION

Pfizer Rx Products and Gene Therapy

Phone: 800-533-4535
Fax: 800-741-4237
Email: USRxCustomerService@pfizer.com
DropShips@pfizer.com

For direct access to specific Products:

Hemophilia Products

Phone: 888-440-8100
Fax: 888-685-5960
Email: Hemophilicustomersupport@pfizer.com

Hemophilia Products Puerto Rico Customers

Phone: 800-981-4748
Fax: 888-685-5960
Email: Hemophilicustomersupport@pfizer.com

Hospital Business Unit

Phone: 844-646-4398
Fax: 262-577-6503
Email: PICustomerService@pfizer.com - Hospitals & Healthcare Providers
PICustomerServiceDWT@pfizer.com - Pfizer Distributors

Hospital Business Unit Puerto Rico Customers

Phone: 800-981-4748, option 2 (Bi-lingual)
Fax: 262-577-6503
Email: PIServicioalClientePR@pfizer.com.

Lucira

Phone: 1-888-LUCIRA-4 (582-4724)
Email: luciraorderprocessing@pfizer.com

Vaccines

Phone: 800-666-7248
Fax: 484-563-0825
Email: USCUSTS@pfizer.com

Vaccines Puerto Rico Customers

Phone: 800-981-4748, option 2 (Bi-lingual)
Fax: 888-685-5960
Email: PRcustomerservice@pfizer.com

For Drug Supply Chain Security Act (DSCSA) related correspondence, please send inquiries to Customer Service via our email: DSCSA@pfizer.com

All orders, whether based upon submitted quotations or not, are subject to acceptance and credit approval by Pfizer. Pfizer reserves the right to restrict order quantities. Pfizer reviews all submitted orders against lists of Restricted Parties maintained by applicable governmental authorities, including lists established under the U.S. Federal Food Drug and Cosmetic Act and the U.S. Foreign Assets Control Regulations. This review may result in orders that are delayed or blocked. Recipients of Pfizer products are required to follow all applicable laws in connection with the purchase, sale, distribution, or use of such Products.

PRICES

All prices are submitted without offer.

Prices are subject to all taxes, excises, or other charges levied by any government



January 1, 2025

(national, state, or local) upon the sale, consumption, or use of the Products listed herein.

PAYMENT TERMS

Products may have unique payment terms as provided by contract or as indicated on the Price List or Product invoice.

Payments submitted via Electronic Funds Transfer (EFT) may add an additional four (4) days to the invoice due date.

Payment must be in the bank on the discount date.

Prompt pay discounts are an encouragement for prompt payment; discounts not taken at time of payment cannot be claimed at a later date.

Credit Card Policy – Pfizer may accept select credit cards as a payment option for direct purchases of Products; however, the prompt pay discount is not available when payment is made by credit card, except for physician offices purchasing selected vaccines. For important information concerning the use of your credit card for the purchase of Products, including additional payment options for selected vaccines, please contact Pfizer Customer Service at 800-666-7248.

PFIZER DISTRIBUTORS

Pfizer distributors may only purchase Products directly from Pfizer, or in the event of a supply shortage only, another Pfizer distributor, with prior written consent from Pfizer. A listing of authorized Pfizer distributors can be found online at www.pfizer.com/pdlist or obtained from our Customer Service team.

Pfizer may revoke Pfizer distributor status at any time.

Products may only be sold to providers operating within the United States (and its territories) who are appropriately licensed by the states/territories in which they dispense or distribute pharmaceutical products, or to other Pfizer distributors. In Puerto Rico, DACO priced Products may only be sold to other Puerto Rico Pfizer distributors or providers operating within Puerto Rico who are appropriately licensed by the Commonwealth of Puerto Rico in which they dispense pharmaceutical products.

Each Pfizer distributor must have a comprehensive program to ensure compliance with the DSCSA, and to assess all offers prior to purchase using a defined procedure that helps identify suspect pharmaceutical products and suspicious orders.

Pfizer has the right to audit or request information on all purchases and sales of Products at any time and to audit processes used to purchase Products from other Pfizer distributors.

Pfizer distributors must maintain their wholesale distributor license in good standing in each state/territory where it has operations and shall immediately upon Pfizer's request, forward a copy of all renewed licenses to Pfizer. Failure to submit a copy of a renewed license to Pfizer may lead to suspension of further shipments of Pfizer Product to such distributor at the applicable location until such license(s) is provided.

Each Pfizer distributor must notify Pfizer within one (1) business day of termination, suspension, revocation, forfeiture or nonrenewal of its wholesale distributor licenses for any location where it has operations.

Any deviation from these Terms of Sale may result in Pfizer terminating its business relationship with a distributor and removal of recognition as a Pfizer distributor.

MINIMUM ORDER/ORDER FREQUENCY

The minimum order amount is \$250.00.

Pfizer reserves the right to reject any order less than \$250.00.

Accounts are limited to no more than one order per week per Product per receiving location.

SHIPPING AND ROUTING

Pfizer reserves the right to ship via a carrier of its choice. Where expedited delivery, special handling or routing of Products listed in Section II of the Product Price List is requested by the customer and is approved by Pfizer, a \$25.00 handling charge and applicable additional shipping charges will be applied to the order. For after-hours or weekend emergency orders, Pfizer may apply a \$250.00 handling charge.

DELIVERY

All deliveries shall be made F.O.B. point of shipment. Title to Products sold shall pass upon delivery of the Products to the carrier. **Customer will notify Pfizer immediately upon receipt of any delivery if any required DSCSA data related to the Products is missing. Pfizer will make commercially reasonable efforts to provide such missing DSCSA data within ten (10) business days from the receipt of the customer's notice.**

DAMAGE OR DELAY IN TRANSIT

If Products arrive in broken or damaged condition, it is the customer's responsibility to ensure that the carrier's agent notes the damage or breakage on the delivery receipt. The transportation company acts as the agent of the customer/purchaser, and Pfizer is not responsible for any loss, damage, or delay with respect to the Products after delivery to the carrier. Pfizer shall assist, when requested, in formulating claims against the carrier, but Pfizer will not assume the responsibility of collecting claims against the carrier.



January 1, 2025

For any loss or damage evident at the time of delivery, customer must make notation on the delivery receipt and report to Pfizer within seven (7) business days of the date of delivery or thirteen (13) days from the invoice date. For concealed loss or damage, customer must report to the carrier and to Pfizer within fifteen (15) days after receipt of the shipment.

In cases in which damage, shortage, or loss is not due to transportation causes, and if upon discovery, a customer promptly reports to Pfizer any such damage, shortage, or loss, Pfizer will investigate such report and take appropriate actions, which may include, but are not limited to, providing even exchange or credit for such damage, shortage, or loss as is directly traceable to any fault or negligence on the part of Pfizer. **To support the investigation, Pfizer requires the serialized data for the reported shortage or reported overage. Without such required information, Pfizer cannot provide the appropriate financial adjustments or supplemental DSCSA data.**

PRODUCT RECALLS

In the event of a Pfizer initiated recall, it is Pfizer's practice to reimburse customer for actual and reasonable expenses incurred in complying with the request as laid out in Pfizer's recall notification. Notwithstanding the foregoing or anything stated herein to the contrary, customer shall be responsible for any and all actual fees incurred by such customer with respect to recalls or market actions initiated by the distributor or recalls, or market actions caused by the customer or directed by the customer.

PERISHABLE PRODUCTS

Certain Products require special temperature storage conditions and precautions in accordance with the caution label attached to each package. With regard to these Products, Pfizer will not accept responsibility for any losses sustained through failure to store or handle as directed by the Product label.

RESTRICTED PRODUCTS

Certain Products have been misused in capital punishment procedures. Such Products are categorized as Restricted Products by a special designation on the Pfizer Product Price List. Purchasers of Restricted Products shall not use, nor resell to entities who may use, Restricted Products in capital punishment procedures. By purchasing Restricted Product(s) from Pfizer or a Pfizer distributor, federal, state and local government agencies, certify that any Restricted Products they acquire shall be used for medically appropriate patient care, and may not be used or resold to any other party for capital punishment uses. Pfizer may, in its discretion, determine which Products are Restricted Products.

CHARGEBACKS

Periodically, Pfizer may recognize the request by a buying group or other Pfizer customer to designate certain Pfizer distributors as their designated Prime Vendor to supply eligible

members with pharmaceutical and health care products. Products that appear on a bid award/contract will be ordered from and shipped to the eligible group members by such Pfizer distributor and invoiced at the current contract prices for each awarded item as notified to such Pfizer distributor by Pfizer.

Pfizer shall furnish such Pfizer distributor with the following information for each bid/contract awarded to Pfizer:

- I. Contract number;
- II. Products under contract;
- III. Contract prices and their effective and expiration dates;
- IV. A list of authorized purchasers; and
- V. Such other information as may be necessary to accurately administer Chargebacks in accordance with) Healthcare Distribution Alliance (HDA) guidelines applicable to such Pfizer distributor.

Pfizer shall use commercially reasonable efforts to provide such information at least five (5) business days prior to the effective date of the bid award/contract. Thereafter, Pfizer shall notify such Pfizer distributor of revisions to a bid award/contract, and any additions to or deletions from the list of authorized purchasers for each bid award/contract. The obligation of Pfizer to make reimbursements available to such Pfizer distributor shall only apply to items sold to the authorized purchaser for "its own use", as defined below. Pfizer distributor shall make commercially reasonable efforts to submit Chargeback requests that are limited to quantities of any item that were purchased for the own use of the authorized purchaser. Pfizer distributor shall notify Pfizer immediately if an authorized purchaser is suspected of using Products for purposes other than own use. In the event that Pfizer determines that an authorized purchaser is not eligible for contract prices, Pfizer distributor shall work with Pfizer to recover all discounts extended via Chargeback to the end customer and shall not deduct from Pfizer any disputed amounts. Thereafter, the Pfizer distributor shall remove such purchaser from all Pfizer contract pricing agreements.

The amount of a Chargeback credit/debit memo will be determined on the basis of the difference between the acquisition price furnished by Pfizer and the bid award/contract price as of the invoice date to the authorized purchaser by such Pfizer distributor. Pfizer shall furnish a list of acquisition prices and updates thereto to such Pfizer distributor whenever changes are made by Pfizer. Contract prices under a bid award/contract are considered confidential and such Pfizer distributor shall not disclose contract prices to anyone other than an authorized purchaser, buying groups representing such authorized purchasers and Pfizer unless requested by an authorized purchaser to support claims involving medical payments under federal, state or local programs.

At least once each month and for each bid award where there are Chargebacks, the Pfizer distributor will send Pfizer an electronic Chargeback request (i.e., HDA



January 1, 2025

established EDI 844 format) which shall contain:

- I. Pfizer distributor's name, address and unique identifiers such as DEA, HIN number and suffix or any other additional identifiers where they exist;
- II. Pfizer distributor's debit memo number;
- III. Each authorized purchaser's DEA number and/or unique identifiers such as 340B ID, HIN number and suffix or any other additional identifiers where they exist;
- IV. The contract number assigned by Pfizer and noticed to the Pfizer distributor;
- V. Quantities, dates and the Pfizer distributor's invoice number for all Products sold to each authorized purchaser;
- VI. The NDC number for each Product;
- VII. The acquisition price for each Product in effect on the date of invoice to the authorized purchaser.
- VIII. The contract price for each Product;
- IX. Quantity of Products returned to the Pfizer distributor that were covered by an earlier Chargeback request;
- X. Extended Chargeback amounts for each Product; and
- XI. Chargeback amount requested for each transaction claimed in each debit memo and total Chargeback amount requested for all debit memos.

Pfizer shall use commercially reasonable efforts to verify the amounts in each Chargeback request and issue initial credit/debit memos in the amounts verified within five (5) to seven (7) business days following receipt of a Chargeback request. Pfizer distributors acknowledge that the contract price for an item must be lower than the corresponding acquisition price for such Pfizer distributor to receive credit. Such Pfizer distributors shall not request Chargeback credit unless the authorized purchaser's acquisition price is higher than the corresponding contract price. Further, Pfizer distributors shall reverse all Chargebacks associated with Products that are returned by Pfizer distributor's customers for resale.

Pfizer distributors shall not submit chargebacks for partial quantities of Product less than the unit of sale as provided in the Price List.

Pfizer distributors shall use the HDA EDI 844 and EDI 849 data sets to send and receive Chargebacks to/from Pfizer electronically, including for original submissions and resubmissions. Pfizer shall provide some type of response (typically in the form of EDI 849, unless there is a systems issue) within thirty (30) days of submission or resubmission of an EDI 844. Pfizer distributors shall refrain from taking any deduction prior to thirty (30) days after submission of any Chargeback for which a Pfizer distributor has not received an EDI 849 response. If Pfizer: (i) does not pay (in whole or in part) and (ii) does not provide a reason for non-payment of a Chargeback via EDI 849, during the first thirty (30) days following submission of a Chargeback request, Pfizer distributor may take a deduction for such Chargeback. Any EDI 849 response from Pfizer shall be considered as Pfizer's request

for payback of any amounts that have been deducted related to the Chargeback request. If Pfizer distributor receives a response from Pfizer that denotes that Pfizer is investigating the request, Pfizer shall have an additional thirty (30) days to provide a determination on eligibility. After this sixty (60) day period following Chargeback submission, the Chargeback is considered closed unless a government audit requires correction or adjustment as described below. Pfizer's determination as to the Chargeback's disposition is final.

Chargebacks must be submitted within six (6) months of such Pfizer distributor's invoice to the authorized purchaser. Failure to submit a Chargeback request within this six (6) month period shall result in a waiver of rights to receive or take a credit with respect to any such Chargeback. Should a Pfizer distributor dispute the amount verified for a particular item covered by a Chargeback request, such Pfizer distributor may resubmit that item so long as such resubmission is done within six (6) months following the original invoice date to the authorized purchaser. Resubmissions made after this six (6) month period need not be considered by Pfizer. In the event of a government audit where new information surfaces that cause corrections or adjustments to prior sales, Chargeback claims can be reopened and resubmitted within twelve (12) months of the original invoice date to an authorized purchaser or as otherwise may be required in a government contract. Pfizer reserves the right to perform random Chargeback verifications. Such verification requests may include, but are not limited to, the invoice copies and proof of delivery, and will be required to be provided to Pfizer within thirty (30) days of the original request. If a response is not received within thirty (30) days, Pfizer will reverse the Chargeback paid by issuing a debit to Pfizer distributor's account. In the event that Pfizer has not already paid a Chargeback subject to verification, payment will be withheld until the requested information is received. Pfizer further reserves the right to perform an on-site audit to verify Chargeback sales. Such on-site audits may be subject to specific contract terms between Pfizer and the Pfizer distributor. In the event an audit reveals a discrepancy between the amounts of credit memos or debit memos issued under these provisions and the amounts verified, Pfizer shall issue a correcting credit memo or debit memo, as may be appropriate. Pfizer reserves the right to offset credits for Chargeback obligations with outstanding past due or previously written off invoices and deductions taken by either the Pfizer distributor or customer.

Pfizer will not reimburse any costs incurred by the Pfizer distributor or group members covering an event of Product non-availability. Chargebacks will only be accepted on Products purchased in accordance with these Terms of Sale.

Pfizer distributors shall use commercially reasonable efforts to ensure that: (i) for any inventory management activities and associated order entry activities on behalf of 340B covered entities enrolled and participating in the 340B Drug Pricing Program, the appropriate contract price is charged to such customers based upon their purchases requiring assignment among three accounts: 340B outpatient use, hospital in-patient use, and 'non-WAC/non-GPO/non-340B' outpatient use; and (ii) in accordance with such



January 1, 2025

covered entity's eligibility as listed on the HRSA website as of the date of purchase. When submitting chargebacks for purchases under the 340B outpatient program, Pfizer distributor shall ensure it includes the appropriate 340B ID on all such chargeback submissions. When submitting chargebacks for all other purchases (including Source Program purchases), Pfizer distributors will make best efforts to include the 340B ID as an alternate identifier for all 340B covered entity accounts. Pfizer distributors must notify Pfizer of the account and contract identifiers it uses to identify purchases by 340B eligible customers for 340B outpatient use, hospital in-patient use, and 'non-WAC/non-GPO/non-340B' outpatient use.

If the Pfizer distributor changes the account or contract identifiers it uses to identify purchases by 340B eligible customers, the Pfizer distributor shall notify Pfizer within five (5) business days of such change. Pfizer distributors shall submit any corrections for order errors or sales for 340B ineligible facilities/accounts that are discovered by either the covered entity or by the Pfizer distributor within five (5) business days of discovery.

PURCHASE FOR OWN USE

Sales by Pfizer to government agencies and other institutions (e.g., federal, state, city, charitable organizations) are made with the express understanding and agreement that the Products purchased by these organizations is subject to the "own use" laws; is for their sole use and may not be commercially sold by them to any other entity or person for further sale or resale.

ALL OTHER CLAIMS

All other claims must be submitted to Pfizer within nine (9) months of the original event upon which the claim is based. Pfizer reserves the right to offset credits for all other claims with outstanding past due or previously written off invoices and deductions taken by either a Pfizer distributor or customer.

NOTICE OF OBLIGATION TO REPORT DISCOUNTS

To the extent that purchaser avails itself of a prompt pay discount in accordance with the terms herein, or otherwise receives a discount from Pfizer in connection with any purchase, direct or indirect, these Terms of Sale shall constitute notice to purchaser of a discount that it may be obligated to report under applicable laws, including, without limitation, the federal anti-kickback statute, 42 U.S.C. § 1320a-7b(b), and its implementing regulations, 42 C.F.R. 1001.952(h) or (i).

PFIZER PHARMACEUTICALS PRODUCT LIABILITY PROTECTION POLICY

In the event of a claim or lawsuit arising out of the dispensing of a Product, it is Pfizer's policy to defend and hold harmless the pharmacist or the pharmacist's employer if the following conditions are met:

- I. If a prescription Product, the prescription Product was properly filled by the pharmacist;
- II. The Product was not improperly stored or packaged;
- III. There is no evidence of negligence or any improper or illegal act by the pharmacist or

- employer;
- IV. The pharmacist has not made express warranties nor provided information inconsistent with the approved product labeling; and
- V. The pharmacist and the pharmacist's employer, if any, provide Pfizer with prompt notice of the claim or lawsuit and fully cooperate with Pfizer in the defense of the claim or lawsuit.



January 1, 2025

RETURN GOODS POLICY

I. Return Goods Policy

All Products (with the exception of Seasonal Vaccines) may be returned on the following basis:

A. Returnable Products: The following Products may be returned by customers for return goods credit without prior approval:

1. Short-dated Products, in the original container and bearing the original label, within six (6) months prior to the expiration date, subject to the exceptions listed **below in NOTES of this Return Goods Policy.**
2. Outdated Products, in the original container and bearing the original label, up to twelve (12) months beyond the expiration date.
3. Discontinued Products.
4. Products damaged in transit or shipped in error by Pfizer.
5. Products lost in transit shall be treated as damaged Products.
6. **Products received without required DSCSA data shall be treated as damaged products if Pfizer fails to provide such required data within 10 business days from notification to Pfizer.**

Notes: Exceptions to above A.1.

- i. No credit will be issued for Products returned more than twelve (12) months beyond its expiration date.***
- ii. For returns resulting from I. A. 4. or 5. above, credit will be issued at full invoice price, including any excise tax where applicable.***
- iii. Partial bottles may be returned, and credit will be issued on the basis of the actual pill count. Credit will not be issued for pill counts in excess of the original container quantity. For liquids, oral powders, syringes, injectables, sponges, inhalation systems, cream and ointment Products, credit will only be issued for intact and unused units of an inner pack. No credit will be issued for any others, including reconstituted Product. For liquid configurations larger than a unit of use, credit will be issued in 25% increments to a maximum of 75% for any opened package.***

B. Non-Returnable (for Credit) Products: Products other than those listed above are defined as not returnable for credit, unless otherwise required by law. This includes, but is not limited to:

1. For Products listed in Section I of the Product Price List, any Product with more than six (6) months dating remaining and any Product that is more than twelve (12) months beyond the Product's expiration date.

2. For Products listed in Section II of the Product Price List, any Product that has not yet expired or that is more than twelve (12) months beyond the Product's expiration date. Private label Products are subject to Section II for purposes of this exception.
3. Packages with trade label removed or unreadable.
4. Repackaged Product.
5. Product that has been in a fire, clearance, bankruptcy, or similar sale.
6. Product sold on a "non-returnable" basis.
7. Products, including items affected by a market withdrawal or a recall, retained more than twelve (12) months beyond the expiration date noted on the package. (Product may be returned for destruction, but no credit will be issued.)
8. Products purchased or otherwise obtained in violation of any Federal, State, or local law or regulation.
9. Products obtained illegally or via diverted means including, without limitation, Products manufactured and/or imported by non-Pfizer sources from countries outside the United States, except as expressly permitted by state law.
10. Products destroyed or damaged from insurable causes such as fire, water, tornado, etc., and Products that have otherwise deteriorated due to conditions occurring after shipment and beyond the control of the manufacturer, such as improper storage, heat, cold, smoke, etc.
11. Products marked "Non-Returnable", "Professional Sample," "Clinical Trial Package," or with similar markings or special labels.
12. Products with a prescription label attached.
13. Vaccine or biological Products purchased through the Federal Vaccines for Children and Adult Programs.
14. The following Products: Zosyn® Frozen Galaxy® containers.
15. Products purchased for clinical trials or donated Products.
16. Partial units of sale of hospital and surgical Products listed in Section II of the Product Price List.
17. **Product is not returnable in the event missing DSCSA data is caused by the customer's processes or system failures, or the customer fails to notify Pfizer of the missing DSCSA data immediately upon receipt of any delivery.**

Note: Pfizer's determination as to the salvage, credit or exchange value of Products returned shall be final. Pfizer reserves the right to destroy returned Products without payment or liability.

II. Replacement Policy for Spoiled Biosimilar and Gene Therapy Products

Subject to the terms below, Pfizer will replace any biosimilar or gene therapy Product ("Biosimilar/GTx Product") that is purchased by a physician office, clinic, or hospital located in the United States that requires, based on the Biosimilar/GTx Product labeling, specific storage and handling requirements and, if applicable, limits on the amount of time that may elapse between when the Biosimilar/GTx Product is reconstituted and when it is



January 1, 2025

administered to a patient, in the event that the Biosimilar/GTx Product becomes spoiled due to one of the following unintentional events:

1. Product was mishandled, dropped, or broken;
2. Product was inappropriately stored or refrigerated, or was frozen, inconsistent with the Product label;
3. There was an admixture error; or
4. Product was reconstituted but not administered due to an unforeseen patient condition or because the patient missed the appointment.

The following additional terms will apply in order for Biosimilar/GTx Products to be replaced pursuant to this Section II under the Return Good Policy (each, a “**Replacement Product**”):

- Biosimilars/GTx Products are eligible for replacement only and no credit will be issued. Only under rare circumstances where replacement is impossible or impracticable, may credit equal to the original invoice amount be issued in lieu of product replacement at Pfizer’s sole discretion.
- Replacement Product must be available in an FDA-approved product quantity. Requests for replacement of partial packs cannot be fulfilled under this policy.
- Samples are not eligible for replacement under this policy.
- Replacement Product can only be shipped to licensed entities.
- Replacement Product is not available if the Biosimilar/GTX Product was administered or if a patient or payor was billed for the Biosimilar/GTx Product.
- Replacement Products are limited to up to five (5) units per incident, based on FDA-approved product quantities, and excludes refrigeration failures due to natural disasters.
- In all cases, replacement of Biosimilar Products is limited to no more than four (4) incidents per rolling twelve (12) month period. Additionally, in all cases, replacement of GTX Products is limited to no more than two (2) incidents per rolling twelve (12) month period.
- All Biosimilar/GTx Product replacement requests made under this Section III are subject to review and approval by Pfizer.

To obtain Replacement Products under this Section III, customers should contact Pfizer Customer Service. Customers are required to submit documentation detailing how the spoilage occurred and to return the Biosimilar/GTx Product. If the spoiled Biosimilar/GTx Product is not returnable (e.g., a broken vial), the customer must attest to how it became unusable and include a photograph of the unreturnable Biosimilar/GTx Product, if available, and submit a certificate attesting to appropriate destruction of the Product. Furthermore, customers are required to attest that the Biosimilar/GTx Product was not administered to any patient and that no patients or payors were billed for the Product.

III. Procedure for Returning Pfizer Pharmaceutical Products

For all customers, returnable items may be returned without prior authorization by

Company representative. Whenever you wish to return these items, pack the material in a container suitable for shipment and include a packing list that identifies each item being returned, the name and address of your company, DEA number, debit memo number, and Pfizer account number.

To ensure proper and timely handling of return, please obtain an Inmar generated return label(s) to affix to your return boxes by using one of the below contact options:

Website: <https://hrm.reskureturns.com>

Email: rarequest@inmar.com

Phone: 800-967-5952

Fax: 817-868-5343

Returns should be sent to the following address for processing:

Inmar Rx Solutions, Inc.
3845 Grand Lakes Way Suite 125
Grand Prairie TX 75050

If returning on behalf of another customer, Product(s) must be segregated by each end customer who is pursuing credit and include that customer’s DEA, HIN or 340B number as well as their debit memo to ensure proper credit. Pfizer reserves the right to issue zero credit for returns that do not include all required information. To facilitate processing of controlled substances (Schedule III-V), please segregate controlled from non-controlled items when returning Product to Pfizer.

All returns shall be made in compliance with all applicable federal and state laws and regulations. Non-direct customers (i.e., those that purchase primarily through wholesalers), see Section B below for additional credit information.

All Products must be returned freight prepaid by the sender, using generally accepted shipment methods. Use a separate packing list for each carton. To facilitate processing of multiple debit memo numbers returned in a single container, please segregate Product by debit memo number to ensure acceptance and accurate credit. Upon receipt of the returned Products and verification of the contents and condition, a credit memorandum will be issued as appropriate.

For products in Section I unless otherwise required by State regulations or specifically set forth herein, credit for customers, other than Pfizer distributor customers that are subject to a DSA, will be issued at the lower of:

1. current list price less 10%, or
2. lowest current contract price less 10%. If there is no current contract, the most recent



January 1, 2025

expired contract within the preceding 3 years will be used, less 10%.

For products in Section II unless otherwise required by State regulations or specifically set forth herein, credit for customers, other than Pfizer distributor customers that are subject to a DSA, will be issued at the lower of:

1. current list price less 50%, or
2. lowest current contract price less 50%. If there is no current contract, the most recent expired contract price within the preceding 3 years, less 50%.

Pfizer distributors that are subject to a DSA will be issued 100% credit at the current list price pursuant to their DSA agreement for Product submitted for credit via a Pfizer Return Authorization. Pfizer distributors should contact Pfizer Customer Service for a Pfizer Return Authorization and additional requirements.

Pfizer will not issue credit or accept charges/deductions for administrative, handling, or freight charges associated with the return of Product to Pfizer. In the event Product received from Pfizer is damaged to such an extent that physical return is impossible, written explanation of the Product involved, nature of damage, and explanation as to why return cannot be made may be submitted to Pfizer for consideration. Pfizer will consider the request and issue no credit, partial credit, or full credit as Pfizer deems appropriate. In all other circumstances, credit or reimbursement will not normally be issued for Product destroyed by customers or third parties.

Pfizer distributors will use commercially reasonable efforts to re-shelf returned Products that are deemed "saleable products" in accordance with such distributors' return goods policies and applicable law and will at all times comply with the return verification requirements under the Drug Supply Chain Security Act (Title II of the Drug Quality and Security Act).

- 1. Non-Direct Accounts:** Customarily, returned Products are channeled through the authorized wholesaler. If returned to Pfizer, appropriate credit will be issued as a credit through your wholesaler. So that we may process these returns, please include a packing list that details the Product being returned, the returning facility's name and address, DEA, HIN or 340B identifier number, and wholesaler name. Should the returning facility's information be incomplete so that Pfizer is unable to identify them, Pfizer reserves the right to issue no reimbursement. If we are unable to identify the returning party's wholesaler, Pfizer will issue credit in the form of a check mailed directly to the facility's address provided. Pfizer will not issue refunds to third party return goods processors.



January 1, 2025

NDC NUMBER LABELER CODES

0005 Wyeth Pharmaceutical Division of Wyeth Holdings LLC
0008 Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
0009 Pharmacia & Upjohn Company LLC
0013 Pfizer Laboratories Div Pfizer Inc
0025 Pfizer Laboratories Div Pfizer Inc
0046 Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
0049 Roerig
0069 Pfizer Laboratories Div Pfizer Inc
0071 Parke-Davis Div of Pfizer Inc
0409 Hospira, Inc
55724 Pfizer Laboratories Div Pfizer Inc
58394 Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
59267 Pfizer Manufacturing Belgium NV
60793 Pfizer Laboratories Div Pfizer Inc
61570 Pfizer Laboratories Div Pfizer Inc
61703 Hospira, Inc.
63010 Agouron Pharmaceuticals, LLC
70255 Array BioPharma Inc.
72618 Pfizer Laboratories Div Pfizer Inc
72786 Global Blood Therapeutics, Inc.
76310 Clinigen Limited

PRICE LIST - INDICATOR KEY

DACO



Product with Price Change



Product Not Available for Sale in PR



Restricted Product

